Table 2:
Gene Alterations Detected on FMI NGS Screening
| Palbociclib (n=32) | |
|---|---|
| CCGA Study Gene Alterations | |
| CCND1 | 26(81%) |
| CCND2 | 3(9%) |
| CCND3 | 2(6%) |
| CDK4 | 1(3%) |
| Number of CCGA Study Gene Alterations | |
| 1 | 32(100%) |
| Other Concomitant Gene Alterations | |
| Short Variants | |
| TP53 | 30(94%) |
| CDKN2A, MLL2 | 8(25%) |
| NFE2L2 | 6(19%) |
| PTEN | 4(13%) |
| ARID1A, LRP1B, PIK3CA | 3(9%) |
| APC, BAP1, KRAS | 2(6%) |
| ATRX, BRCA2, BRIP1, CREBBP, DAXX, DNMT3A, EZH2, FANCA, FBXW7, FLT4, GRIN2A, IGF1, IKZF1, KLHL6, MET, NCOR1, NF1, NF2, NOTCH1, NOTCH3, NOTCH4, SF3B1, STAT4, STK11, TET2, TRRAP, TSC2, WT1 | 1(3%) |
| Copy Number Alterations | |
| FGF19, FGF3, FGF4 | 24(75%) |
| SOX2 | 16(50%) |
| PIK3CA | 11(34%) |
| CDKN2A | 10(31%) |
| CDKN2B | 9(28%) |
| FGF12, MYC | 6(19%) |
| KRAS | 5(16%) |
| EPHB1, FGFR1, MYST3, REL, ZNF703 | 3(9%) |
| AKT2, EGFR, EMSY, ERBB2, FGF23, FGF6, JAK2, KDM5A, KDR, PTEN | 2(6%) |
| AKT3, BCL2L2, CCNE1, CDK4, IGF1R, IKBKE, KDM6A, KIT, LRP1B, MDM2, MDM4, NFKBIA, NKX2–1, RICTOR, STK11, TP53 | 1(3%) |
| Rearrangements | |
| LRP1B | 3(9%) |
| ABL1, MLH1, MLL2, PIK3R2 | 1(3%) |